A Randomised, Double-Blind, Two-Period Crossover Study to Assess the Effect of AZD6140 on Uric Acid Levels in Healthy Male Volunteers.

Trial Profile

A Randomised, Double-Blind, Two-Period Crossover Study to Assess the Effect of AZD6140 on Uric Acid Levels in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2011

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Thrombosis
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 21 Dec 2011 Results published in the Clinical Pharmacology and Therapeutics.
    • 21 Jan 2009 Planned number added (24) as reported by ClinicalTrials.gov.
    • 21 Jan 2009 Actual end date changed from Sep 2008 to Oct 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top